

O,00-1  
N,N1-2


2

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,N

G2 Ak,X,A,NO2,CN,C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:30:31 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2001 TO ITERATE

100.0% PROCESSED 2000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 37337 TO 42703

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 10:30:48 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 37122 TO ITERATE

100.0% PROCESSED 37122 ITERATIONS

8 ANSWERS

SEARCH TIME: 00.00.01

L3 8 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 10:30:56 ON 21 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Sep 2006 VOL 145 ISS 13

FILE LAST UPDATED: 20 Sep 2006 (20060920/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 1 L3


=> d ibib abs hitstr

OWN  
WORK

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:927172 CAPLUS  
 DOCUMENT NUMBER: 141:395567  
 TITLE: Preparation of substituted pyridazines and analogs  
 for  
 treatment of TNF- $\alpha$ , IL-1 $\beta$ , IL-6, and/or  
 IL-8 mediated disorders  
 Dominguez, Celis; Goldberg, Martin H.; Tamayo, Nuria  
 A.  
 PATENT ASSIGNEE(S): Amgen Inc., USA  
 SOURCE: PCT Int. Appl., 46 pp.  
 CODEN: PIXX22  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094379	A2	20041104	WO 2004-US11953	20040415
WO 2004094379	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004254178	A1	20041216	US 2004-826982	20040415
EP 1628665	A2	20060301	EP 2004-750293	20040415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
HR				
PRIORITY APPL. INFO.: US 2003-463697P P 20030416				
WO 2004-US11953 W 20040415				
OTHER SOURCE(S): MARPAT 141:395567				
GI				

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I [wherein X1, X2 = independently (un)substituted CH, N; with the proviso that at least one of X1 and X2 = N; R1 = (halo)alkyl, CN,


NO<sub>2</sub>, acyl, carboxy, carbamoyl, alkoxy, sulfamoyl, ureido, etc.; R2 = alkyl, Ph, PhCH<sub>2</sub>, heterocyclyl, etc.; R3, R4 = independently (un)substituted Ph, naphthyl, heterocyclyl; or pharmaceutically acceptable salts thereof] were prepared as TNF- $\alpha$ , IL-1 $\beta$ , IL-6, and/or IL-8 inhibitors. For example, a multi-step synthesis concluding with the reaction of 4-[5-(2-methanesulfonylpyrimidin-4-yl)-4-methyl-6-(3-trifluoromethylphenyl)pyridazin-3-yl]piperidine-1-carboxylic acid benzyl ester and (S)-(-)-1-phenylethylamine gave II. The latter inhibited lipopolysaccharide-activated THP1 cell TNF- $\alpha$  production with IC<sub>50</sub> <20  $\mu$ M. Thus, I and their pharmaceutical compns. are useful for the treatment of inflammation, rheumatoid arthritis, Paget's disease, osteoporosis, multiple myeloma, uveitis, acute or chronic myelogenous leukemia, pancreatic b cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic

rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type

II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses, or herpes zoster infection (no data).


IT 786705-13-3P, 4-[4-methyl-5-(2-methylsulfonylpyrimidin-4-yl)-6-(3-trifluoromethylphenyl)pyridazin-3-yl]piperidine-1-carboxylic acid benzyl ester 786705-15-5P, 4-[5-(2-methylsulfonylpyrimidin-4-yl)-4-methyl-6-(3-trifluoromethylphenyl)pyridazin-3-yl]piperidine-1-carboxylic

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 acid benzyl ester 786705-17-7P, 4-[4-methyl-5-[2-(1-phenylethylamino)pyrimidin-4-yl]-6-(3-trifluoromethylphenyl)pyridazin-3-yl]piperidine-1-carboxylic acid benzyl ester 786705-19-9P, [4-[5-Methyl-6-(piperidin-4-yl)-3-(3-trifluoromethylphenyl)pyridazin-4-yl]pyrimidin-2-yl](1-phenylethyl)amine 786705-21-3P, 2-Hydroxy-1-[4-[4-methyl-5-[2-(1-phenylethylamino)pyrimidin-4-yl]-6-(3-trifluoromethylphenyl)pyridazin-3-yl]piperidin-1-yl]propan-1-one 786705-23-5P, (S)-4-[4-methyl-5-[2-(1-phenylethylamino)pyrimidin-4-yl]-6-(3-trifluoromethylphenyl)pyridazin-3-yl]piperidine-1-carboxylic acid benzyl ester 786705-25-7P, [4-[5-Methyl-6-(piperidin-4-yl)-3-(3-trifluoromethylphenyl)pyridazin-4-yl]pyrimidin-2-yl]((S)-1-phenylethyl)amine 786705-27-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (TNF and/or IL inhibitor; prepn. of substituted pyridazines and analogs as TNF and IL inhibitors for treatment inflammation, pain, and other disorders)  
 RN 786705-13-3 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[4-methyl-5-[2-(methylsulfonyl)-6-(3-(trifluoromethyl)phenyl)-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 786705-15-5 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[4-methyl-5-[2-(methylsulfonyl)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 786705-17-7 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[4-methyl-5-[2-[(1-phenylethyl)amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 786705-19-9 CAPLUS  
 CN 2-Pyrimidinamine, 4-[5-methyl-6-(4-piperidinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 786705-21-3 CAPLUS  
 CN Piperidine, 1-(2-hydroxy-1-oxopropyl)-4-[4-methyl-5-[2-[(1S)-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 786705-23-5 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[4-methyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 786705-27-9 CAPLUS  
 CN Piperidine, 1-[(2R)-2-hydroxy-1-oxopropyl]-4-[4-methyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




OH

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 786705-25-7 CAPLUS  
 CN 2-Pyrimidinamine, 4-[5-methyl-6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 2-A